603858.SH
步长制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.18
−2.19%Year over year
Reported trailing growth
- Revenue
- +4.7%
- EBITDA
- —
- EBIT
- +838.5%
- EPS
- +208.0%
- Free cash flow
- -75.5%
- Operating cash flow
- -71.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -7.4%
- EBITDA
- +2.7%
- EBIT
- +13.9%
- Net income
- +6.4%
- EPS
- +8.8%
- Free cash flow
- -22.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026